期刊论文Nonclinical Safety Assessment of Next Generation Biologicals: NanobodiesⓇ复制

DOI:复制

文献链接:复制

其他信息:

S Jacobs, S De Boever, MP Bouche…
… Primate Research in …, 2012
books.google.com
Nanobodies® are a novel class of therapeutic proteins based on the smallest functional fragments of heavy-chain antibodies, naturally occurring in Camelidae. They are developed for a wide range of disease indications including haematology, inflammation, oncology, and pulmonary disease. Ablynx has approximately 25 Nanobody programmes (both partnered and wholly-owned) in its product pipeline, and seven Nanobodies have entered clinical development (status: first half of 2012). The first Nanobody achieved clinical proof-of …